| Primary |
| Glaucoma |
92.9% |
| Intraocular Pressure Increased |
7.1% |
|
| Product Substitution Issue |
15.8% |
| Vision Blurred |
10.5% |
| Choroidal Detachment |
5.3% |
| Drug Hypersensitivity |
5.3% |
| Dysgeusia |
5.3% |
| Ear Pain |
5.3% |
| Eye Irritation |
5.3% |
| Intraocular Pressure Increased |
5.3% |
| Lacrimation Increased |
5.3% |
| Polyneuropathy |
5.3% |
| Prostatic Specific Antigen Increased |
5.3% |
| Spinal Fracture |
5.3% |
| Swelling Face |
5.3% |
| Toxic Epidermal Necrolysis |
5.3% |
| Tremor |
5.3% |
| Vitreous Disorder |
5.3% |
|
| Secondary |
| Intraocular Pressure Increased |
28.6% |
| Glaucoma |
23.8% |
| Product Used For Unknown Indication |
9.0% |
| Open Angle Glaucoma |
5.8% |
| Anterior Chamber Disorder |
5.3% |
| Endophthalmitis |
3.7% |
| Anaemia |
3.2% |
| Atrial Fibrillation |
3.2% |
| Constipation |
3.2% |
| Drug Use For Unknown Indication |
3.2% |
| Punctate Keratitis |
2.1% |
| Eye Disorder |
1.6% |
| Hypertension |
1.6% |
| Normal Tension Glaucoma |
1.6% |
| Ectropion |
1.1% |
| Intraocular Pressure Test Abnormal |
1.1% |
| Age-related Macular Degeneration |
0.5% |
| Antiviral Prophylaxis |
0.5% |
| Benign Neoplasm Of Prostate |
0.5% |
| Benign Prostatic Hyperplasia |
0.5% |
|
| Visual Acuity Reduced |
25.0% |
| Intraocular Pressure Increased |
10.4% |
| Hypotony Of Eye |
6.3% |
| Nephropathy Toxic |
6.3% |
| Renal Impairment |
6.3% |
| Vision Blurred |
6.3% |
| Drug Ineffective |
4.2% |
| Eye Irritation |
4.2% |
| Surgery |
4.2% |
| Throat Irritation |
4.2% |
| Vitreous Haemorrhage |
4.2% |
| Anterior Chamber Disorder |
2.1% |
| Choroidal Detachment |
2.1% |
| Depression |
2.1% |
| Dizziness |
2.1% |
| Flat Anterior Chamber Of Eye |
2.1% |
| Heart Rate Irregular |
2.1% |
| Hypertension |
2.1% |
| Induced Labour |
2.1% |
| Intraocular Pressure Fluctuation |
2.1% |
|
| Concomitant |
| Glaucoma |
27.1% |
| Product Used For Unknown Indication |
23.0% |
| Hypertension |
8.9% |
| Drug Use For Unknown Indication |
4.8% |
| Intraocular Pressure Increased |
4.2% |
| Bacteraemia |
4.1% |
| Pain |
2.9% |
| Blood Cholesterol Increased |
2.7% |
| Diabetes Mellitus |
2.7% |
| Arthralgia |
2.4% |
| Osteoporosis |
2.4% |
| Prophylaxis |
2.4% |
| Depression |
2.1% |
| Type 2 Diabetes Mellitus |
2.1% |
| Prostatic Disorder |
1.8% |
| Macular Degeneration |
1.4% |
| Colorectal Cancer Metastatic |
1.3% |
| Epilepsy |
1.3% |
| Hypothyroidism |
1.2% |
| Myocardial Ischaemia |
1.2% |
|
| Intraocular Pressure Increased |
16.7% |
| Acute Generalised Exanthematous Pustulosis |
12.5% |
| Drug Ineffective |
7.3% |
| Vomiting |
6.3% |
| Toxic Epidermal Necrolysis |
5.2% |
| Encephalopathy |
4.2% |
| Mental Disorder |
4.2% |
| Pneumonia |
4.2% |
| Product Dropper Issue |
4.2% |
| Visual Acuity Reduced |
4.2% |
| Blood Pressure Increased |
3.1% |
| Constipation |
3.1% |
| Dyspnoea |
3.1% |
| Glaucoma |
3.1% |
| Hemiparesis |
3.1% |
| Injection Site Pain |
3.1% |
| International Normalised Ratio Increased |
3.1% |
| Malaise |
3.1% |
| Muscle Spasms |
3.1% |
| Muscular Weakness |
3.1% |
|
